pharma · Diabetes Mellitus · Hemophilia A
Takeda
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 1993
- Employees
- 1,617
- Programs
- 1179
- Drugs
- 359
- Patents
- 1436
TAK-079-3001
Phase 3 · small molecule · IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)
TAK-079-3001 for IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease) is a Phase 3 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Internal code TAK-079-3001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Takeda
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)
- Status
- active
- Trials
- 1